Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells.

We investigated the antitumor activity of Adriamycin on a monocytic-like cancer cell line U-937 after its binding on polymethacrylate nanospheres (diameter, 270-350 nm). Compared to free Adramycin (F-ADR), nanosphere-bound Adriamycin (B-ADR) exhibits a 3-fold enhancement of cytotoxicity, as determined by cell growth inhibition and DNA synthesis, after continuous exposure to 0.02 and 0.04 microgram/ml. The 90% growth inhibition concentration was 0.051 microgram/ml for F-ADR and was 0.018 microgram/ml for B-ADR (P less than 0.001). Furthermore, the nanosphere densities per cell play an important role since for the same drug concentration the higher the density increases, the better the activity is. Indeed, after 4 days of incubation in a medium containing 160 nanospheres at 0.5 fg/cell, the cell counts were 62.8 +/- 12.8% (SD) of the initial inoculum and they were only 16.1 +/- 0.1% after incubation in a medium containing 800 nanospheres at 0.1 fg/cell (P less than 0.001). A comparable enhancement of activity regarding the nanosphere densities was observed after a 24-h exposure to 0.02 and 0.05 microgram/ml. Short-term uptake studies showed that B-ADR accumulation was higher with B-ADR than with F-ADR. In addition, the efflux kinetics was modified. For cells exposed to F-ADR for 4 h, the efflux half-life was 23.7 +/- 7.7 h and the area to infinity under the efflux curve was 8.6 +/- 2.8 micrograms/mg protein x h-1. For cells exposed to B-ADR, the efflux half-life increased to 85.9 +/- 19.2 h and the area to infinity under the efflux curve to 29.6 +/- 6.6 micrograms/mg protein x h-1 (P less than 0.001). Electron transmission microscopy and previous findings have revealed that B-ADR was well internalized into cells. Our data support the hypothesis that B-ADR acts as an intracellular drug release complex after endocytosis. The findings regarding the number of nanospheres per cell and dose-effect relationships are consistent with mechanisms of drug actions extending to membrane domains.

[1]  E. Tomlinson,et al.  Concomitant adsorption and stability of some anthracycline antibiotics. , 1982, Journal of pharmaceutical sciences.

[2]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, Federation proceedings.

[3]  D. Kessel,et al.  Membrane alterations associated with progressive adriamycin resistance. , 1982, Biochemical pharmacology.

[4]  P. Edman,et al.  Acrylic microspheres in vivo IX: Blood elimination kinetics and organ distribution of microparticles with different surface characteristics. , 1983, Journal of pharmaceutical sciences.

[5]  T. Masuko,et al.  Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody. , 1983, Cancer research.

[6]  R. Johnson,et al.  Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. , 1979, Cancer research.

[7]  J Kreuter,et al.  Evaluation of nanoparticles as drug-delivery systems. III: materials, stability, toxicity, possibilities of targeting, and use. , 1983, Pharmaceutica acta Helvetiae.

[8]  M. V. van Lancker,et al.  Quantitative determination of low concentrations of adriamycin in plasma and cell cultures, using a volatile extraction buffer. , 1986, Journal of chromatography.

[9]  M. Chitnis,et al.  In vitro enhancement of adriamycin cytotoxicity in human myeloid leukemia cells exposed to verapamil. , 1984, Oncology.

[10]  T. Skovsgaard.  Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. , 1978, Cancer research.

[11]  G. Gregoriadis.  Targeting of drugs , 1977, Nature.

[12]  R. Ganapathi,et al.  Intracellular adriamycin levels and cytotoxicity in adriamycin-sensitive and adriamycin-resistant P388 mouse leukemia cells. , 1982, Journal of the National Cancer Institute.

[13]  T. Tsuruo,et al.  Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. , 1983, Cancer research.

[14]  M. Fox,et al.  Antitumor Drug Resistance , 1984, Handbook of Experimental Pharmacology.

[15]  M. Center,et al.  Isolation and characterization of adriamycin-resistant HL-60 cells which are not defective in the initial intracellular accumulation of drug. , 1986, Cancer research.

[16]  G. Goldenberg,et al.  Alterations of Drug Transport , 1984 .

[17]  S. Davis,et al.  The organ uptake of intravenously administered colloidal particles can be altered using a non‐ionic surfactant (Poloxamer 338) , 1984, FEBS letters.

[18]  K. Rogers,et al.  Synthesis of adriamycin-coupled polyglutaraldehyde microspheres and evaluation of their cytostatic activity. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E. Hartree,et al.  Determination of protein: a modification of the Lowry method that gives a linear photometric response. , 1972, Analytical biochemistry.

[20]  K. Nilsson,et al.  Establishment and characterization of a human histiocytic lymphoma cell line (U‐937) , 1976, International journal of cancer.

[21]  P. Couvreur,et al.  Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. , 1980, European journal of cancer.

[22]  P. Couvreur,et al.  Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. , 1982, Journal of pharmaceutical sciences.

[23]  M. Dalmark,et al.  A Fickian diffusion transport process with features of transport catalysis. Doxorubicin transport in human red blood cells , 1981, The Journal of general physiology.

[24]  C. Duve,et al.  Chemotherapy through lysosomes with a DNA-daunorubicin complex. , 1972, Nature: New biology.

[25]  Y. Barenholz,et al.  Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. , 1986, Journal of the National Cancer Institute.

[26]  A. Trouet,et al.  Experimental leukemia chemotherapy with a "lysosomotropic" adriamycin-DNA complex. , 1974, European journal of cancer.

[27]  J. Kreuter,et al.  Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. , 1983, Oncology.

[28]  Tetsuro Kato,et al.  Sustained‐release properties of microencapsulated mitomycin C with ethylcellulose infused into the renal artery of the dog , 1980, Cancer.

[29]  B I Sikic,et al.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. , 1985, Cancer research.

[30]  F. Wilcoxon,et al.  A simplified method of evaluating dose-effect experiments. , 1948, The Journal of pharmacology and experimental therapeutics.